Business Review · Miami Stem Cell + BetterStem

Section 1 · Executive Snapshot

Where we are. What's broken. What's the upside.

The audit trail (sources), the methodological rules, the KPI dashboard, and the three-and-three diagnostic — in that order. The reader sees the rigor before the numbers.

⊕ Data Sources — What's Behind This Analysis

Audit drew from 12 sources. 7 ingested, 3 pending, 2 blocked.

✓ Ingested

Meta Ads — campaign performance

Apr 8 → May 8, 2026 · 31 days · 3 campaigns · $5,043.65 spend · 94 leads + 120 messenger conversations. Powers FB Ads CPM/CPC/CTR + lead volume claims.

✓ Ingested

Google Analytics 4 — traffic acquisition

Jan 11 → May 8, 2026 · 2,134 sessions / 1,808 users L90D. Powers traffic mix + engagement rate + monthly trend timeline.

✓ Ingested

Google Analytics 4 — events

Top events L90D: page_view 3,159, session_start 2,123, form_start 7. Powers form-conversion baseline + tracking-gap diagnostic.

✓ Ingested

Fireflies — Kickoff Transcript

2026-04-29 · Greice Murphy + Remco Bos · 90 min. Powers stated lead volume (400-500/mo MSC), upsell rate (70-80%), revenue ($2-3.5M), founder positioning.

✓ Ingested

Brand Brain — full corpus

brand_master.md, personas.md (6), offers_and_pricing.md, products_overview.md, objections.md (10). Powers ICP, pricing comparisons, voice guardrails.

✓ Ingested

Competitive Set — 12 profiles

Regenexx, QC Kinetix, Panama SCI, DVCSTEM, Beike, Duke, traditional ortho, US Stem Cell Inc. (FDA shutdown), South FL clinics, ABA conventional. Powers positioning map + acquisition-strategy table.

✓ Ingested

Strategy — Lever Priorities

30_strategy/lever-priorities.md (2026-05-08). Powers opportunity sizing for L1 (CRM Reactivation), L2 (Google Ads), L3 (BetterStem Launch).

⌛ Pending

GA4 — key_events configuration

0 key_events recorded across 2,134 L90D sessions. Form_start fires (7) but is not flagged as conversion. Resolves CAC confidence M → H once events configured + 30 days of data accrue.

⌛ Pending

UTM hygiene — campaign tagging

53% of GA4 sessions tagged "(direct)", 29% "(referral)" — paid social campaigns are not flowing UTMs to GA4. Resolves true channel mix once tags deploy across Meta + landing pages.

⌛ Pending

GHL — daily_metrics sync

Connection exists, 0 rows flowing. Lead volume is currently from Greice's verbal claim (400-500/mo). Resolves lead-volume confidence M → H once the GHL CRM data sync is operational.

✗ Blocked

Patient-level revenue / treated-patient unit

Not in our connected platforms — Greice has it in GHL + clinic billing systems but it doesn't yet flow to the analytics layer. Workaround: derive from leads × stated funnel rates × stated ticket. Resolves once the revenue source is selected and stitched.

✗ Blocked

BetterStem — performance data

Pre-revenue startup. ~10 patients in pipeline lifetime. Zero ad spend, zero website analytics, zero email infrastructure. All BetterStem analysis is from category research + ICP work + the founder's stated targets.

⊕ Methodological Notes — How We Treat Uncertainty

Five rules govern how this Business Review handles incomplete data. Every numeric claim is tagged.

Channel-measurement gap. Meta's "lead" action is a form-fill, not a treated patient. Stated CPA ≠ true CPA. Where the conversion event ≠ the business's true unit, we present both and N/A the right side until attribution is stitched.

Confidence-tag interpretation. H = direct from primary data (platform-verified, kickoff hard fact). M = derived/estimated. L = single-source or unvalidated. Treat L tags as working assumptions, not findings.

Derived metrics show the math. Effective cost-per-treated-patient, blended ticket, and any KPI built from a multiplier carry a derivation block with a sensitivity range and a path to upgrade confidence.

N/A is shown, not hidden. Google Ads, GHL leads, BetterStem performance, peer-reviewed clinical evidence — when missing, they appear as visible N/A markers with the unblock path. The visibility gap is part of the diagnosis.

Prior decision-makers are encoded signal. The current paid agency, the WordPress SEO partner, the GHL setup by Jana — their choices reflect context the BR doesn't have. Where this BR contradicts an incumbent decision, it's named — not overridden without measurement.

Confidence Legend: H Direct primary data M Derived / estimated L Single-source / unvalidated

⊕ Central Diagnostic

The MSC engine works — 8,500 procedures, 70-80% upsell, ~$3M/yr H (kickoff). The BetterStem engine doesn't yet exist — pre-revenue, ~10 patients in pipeline, $0 spend H. The constraint across both is measurement, not motion. $5,043 of Meta spend is generating 94 leads + 120 conversations in 31 days H, but 0 of those flow as conversions through GA4, 53% of sessions are "(direct)" because UTMs aren't deployed, and the GHL CRM data sync is silent. Until the data layer is operational, every CAC, ROAS, and reallocation decision sits on a proxy. Foundation move (Days 0-14): stitch the measurement layer. Then everything else compounds.

Lead Volume / mo (MSC)

400–500 M

→ Stated kickoff

GHL sync: blocked

Meta Ads Spend (L30D)

$5,044 H

3 campaigns · 31 days

$163/day avg

Meta CPM (L30D)

$40.86 H

↑ vs benchmark

Med. cat. avg: $15–25

FB Leads (L30D)

94 H

+ 120 messenger

Stated CPL: $54

GA4 Sessions (L90D)

2,134 H

→ ~24/day

Engaged: 38.5%

GA4 Key Events (L90D)

0 H

measurement broken

form_start fires only: 7

⚠ Top 3 Issues — Constraining Performance Today

Conversion measurement is broken end-to-end. 0 GA4 key_events tracked across 2,134 L90D sessions H; 53% of sessions tagged "(direct)" H; GHL CRM data sync empty H. → Every CAC, ROAS, and reallocation decision is a proxy

Single-channel, single-creative concentration. 74% of Meta spend in one campaign ($3,735 of $5,044) H; 3 active campaigns in 31 days H; one Hair Loss campaign ($1,008) sits outside FL SB 1768's authorized scope H. → Creative-fatigue risk + regulatory exposure

BetterStem has no acquisition engine. Zero Meta campaigns H, zero email, zero parent-community presence, zero testimonials, ~10 patients in pipeline H. → Offshore competitors compound 20-yr parent-community head-start every month

↑ Top 3 Opportunities — Where the Upside Sits

Stitch the measurement layer (foundation). UTMs across all paid + GA4 key_events config + GHL CRM data sync. Days 1-14. → Unblocks every other lever; upgrades L→M and M→H confidence on ~80% of KPIs

CRM Reactivation (highest immediate ROI). 3,000-4,000 GHL contacts H, ~1-3% reactivation rate M, ~$10K blended ticket. → +$10-30K/mo, ~$0 CAC, 14-21 days to first revenue

BetterStem launch playbook. Right-to-Try moat + EY-recognized founder + zero offshore competitor with US legal recourse H. Path to first revenue in 60 days. → +$62-125K/mo at maturity (5-10 patients × $12.5K) L

Section 2 · Current State Diagnosis

Funnel · Channel Mix · Creative Patterns

Three audit lenses. The funnel tells us where the engine breaks. The channel mix tells us where structural risk is concentrated. The creative section tells us why category-winning brands compound where MSC + BetterStem don't.

Funnel Performance & The Primary Growth Constraint

The funnel can't be fully diagnosed because the data layer isn't operational. The 5-stage patient funnel below combines what's verified from platform data (Meta sessions + leads, GA4 events) with what's stated in the kickoff (qualified leads, show rate, close rate, upsell). The constraint is one stage upstream of the funnel itself: measurement. Until events flow, every leak we name is a working hypothesis, not a finding.

L90D · MSC
combined channels

Sessions / Reach

2,134 GA4 sessions + 123K FB impressions 100%

↓ FB CTR 2.83% · GA4 engaged 38.5% H

Inquiries / Leads

~400-500 / mo (MSC stated) FB: 94 in 30d H

↓ ~20% qualification · "money + no cancer" gate M

Qualified

80-100 qualified leads / mo ~20%

↓ ~60% show · cat. benchmark 65-70% M

Consult Show

48-60 consultations ~12%

↓ ~60% close · 70-80% then add multi-joint upsell H

Treatment + Upsell

29-36 patients · $10-12K blended ticket ~7%

Sessions L90D H

2,134

~24 / day · Jan-May 2026

FB Leads L30D H

+120 messenger conv.

MSC Show Rate M

~60%

vs. 65-70% benchmark

Multi-Joint Upsell H

70-80%

drives blended ticket

⊕ Primary Growth Constraint

The constraint is measurement infrastructure, not funnel conversion.

Three breakages compound: (1) 0 GA4 key_events recorded across 2,134 L90D sessions H — form_start fires (7 events) but isn't flagged as conversion; (2) 53% "(direct)" + 29% "(referral)" means 82% of GA4 traffic is unattributable H — paid social isn't flowing UTMs; (3) GHL CRM daily metrics aren't flowing H — the lead system of record isn't piped. Net effect: $5,044 of Meta spend generated 94 leads + 120 conversations H, but neither GA4 nor the CRM can confirm what happened next. Stated CPL ($54) is real; Cost-Per-Treated-Patient is unmeasurable from primary data.

Strategic implication: Solving measurement is the highest-leverage single move in the engagement. Every other lever (CRM reactivation, Google Ads scale, BetterStem launch, show-rate optimization) sits downstream of attribution. Days 0-14: stitch the layer. Days 14+: every reallocation decision has confidence behind it.

Channel Mix — Imbalance & Dependency Risk

⊕ Structural Imbalance + Dependency Risk

100% of measurable paid acquisition is on Meta. Email is structurally absent. CRM is dormant. BetterStem has no engine. The mix isn't just narrow — it's leaving compounding levers untouched.

Over-Concentrated · Risk

Meta Ads — Single Campaign

$3,735 of $5,044 (74%) in "Virtual Consult — Florida State" H · only 3 active campaigns

If this one campaign fatigues or gets paused (frequency, policy violation, audit), 74% of the paid engine vanishes overnight.

Under-Invested · Margin Lever

Email / SMS / Lifecycle

$0 spend · 0 active flows · 0 segmentation H · category-leading clinics see 20-30% revenue contribution

Stated 400-500 leads/mo enter, ~30 close, the rest are unowned. The lowest-CAC channel is structurally absent.

Latent · Compounding Asset

CRM Reactivation (3,500 GHL)

3,000-4,000 dormant contacts H · 1-3% reactivation × $10K = $10-30K/mo M

Every contact already qualified once. Highest-intent pool in the entire stack. ~$0 CAC. Untouched.

GA4 Session Mix · L90D H

2,134

Sessions

(direct) 53%

(referral) 29%

(organic) 13%

(not set) 5%

Stated CPL by Channel · target $50 H

$50 target

Meta Ads

$54 stated

$54

Google Ads

N/A — no campaigns

N/A

Organic / SEO

N/A — 13% sessions, 0 events

N/A

Referral / Yelp

N/A — untracked

N/A

Email / CRM

$0 (not active)

Channel	Spend / mo	Stated CPA	Volume Signal	Verdict
Meta Ads (paid social)	~$5,044 H	$54 / FB-lead H	94 leads + 120 messenger / 30d	Concentrated
Google Ads	N/A — no campaigns active H	—	—	Not running
Organic / SEO (WP, 8 posts/wk)	$0 direct (agency retainer) L	N/A · 0 GA4 conversions tagged	274 organic sessions / 90d	Untracked
Referral / Yelp / GMB	$0 direct	N/A · attribution broken	630 sessions / 90d (29%)	Hidden
Direct / Branded	$0 direct	N/A	1,126 sessions / 90d (53%)	Inflated by missing UTMs
Email / SMS / Lifecycle	$0 — not active H	—	0 flows · 0 segmentation	Absent
CRM Reactivation	$0 — dormant H	~$0 CAC (latent)	3,000-4,000 GHL contacts	Untapped

⊕ Derived Metric — True Cost Per Treated Patient

Stated CPL ($54) is the platform's measurement. True cost-per-treated-patient is the business unit — and it requires a chain of derived multipliers to land.

Meta Spend (L30D)

$5,044 H

Meta Ads · last 31 days

FB Leads × Funnel

94 × ~36% M

60% show × 60% close

Cost / Treated Patient

~$148 M

vs. ~$10K blended ticket

Anchored: $5,044 spend, 94 FB-tracked leads — direct from Meta. Working assumption: FB lead quality matches MSC's stated 36% lead-to-treated rate — kickoff testimony, not platform-verified. Sensitivity: if FB leads convert at 50% of MSC org rate (18% effective), true cost = $297 / patient. At 150% (54%), true cost = $99. Resolution path: stitch GHL CRM data flow + tag FB leads with source attribution → 30 days of cohorted data → upgrades M → H. Until then: stated CPL is real, true CPA is directional.

Stated CPL by Channel H

Meta Ads

$54

Google Ads

N/A

Organic

N/A

Referral

N/A

Cost / Treated Patient (true unit) M

Meta Ads

~$148 derived

~$148

Google Ads

N/A

Organic

N/A

Referral

N/A

⚠

Why these two charts disagree: Meta's "lead" event is a form-fill or messenger contact — not a treated patient. The right-hand chart's value is derived from MSC's stated funnel (60% show × 60% close). Until GHL syncs and lead source carries through to billing, every other channel must show N/A. Channel reallocation decisions should not be made from the left chart alone.

⊕ 12-Month Primary KPI Timeline — Sessions / mo + Meta Spend

The shape over time matters more than any single point estimate. Sessions are visible from Jan 2026 forward; Meta spend appeared April 2026. The analytics layer is younger than the marketing engine — most pre-2026 history is N/A.

N/A

361

479

898

648

235*

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

May 26

What unblocks the gaps: GA4 history pre-Jan 2026 either wasn't tracked or hasn't been ingested by Fivetran. Sessions peaked at 898 in March 2026, dropped 28% in April (when Meta spend launched at $3,816 — counter-intuitive). May 2026 (235*) is partial-month through May 8. Resolution path: backfill GA4 history (if available), confirm whether March peak was campaign-driven or organic, attribute the April drop. Hypothesis (not finding): Meta paid traffic landing on pages that aren't tagged for GA4 — would explain spend up + attributed sessions down.

Creative Patterns — What's Winning vs. What's Running

⊕ Category Creative Patterns vs. Current Creative

Cash-pay regenerative medicine is a high-trust, high-objection category. Category-winning brands lead with founder credibility, peer-validated outcomes, and patient-story video. Current creative is one campaign deep — virtual consultation, single format.

↑ What's Winning in the Category

Hook

Founder-direct ("16 years, 8,500 procedures, what we won't promise") · patient-pain-specific opener · before/after-day-1

Format

UGC patient testimonials · founder selfie-style explainers · objection-response shorts (FAQ → answer in 30s)

Source

First-party patient stories · founder voice · clinical staff intros · facility tours

Authority

Specific numbers (procedures, years), regulatory framework named, transparent about limitations

⚠ What's Running Today

Hook

Generic "Virtual Consult — Florida State" — no founder voice, no patient story, no specificity

Format

3 campaigns over 31d H · format breakdown not yet pulled · no UGC pipeline · no testimonial collection

Source

Agency-produced — likely stock or staff photography. Greice's voice (the moat) is absent.

Authority

Generic offer-driven · no procedure count, no Right-to-Try framework named, no founder credentials

The category-winning pattern is credibility, not promotion. MSC's founder + 16-year track record + Right-to-Try moat are exactly what this category rewards — but they aren't appearing in the creative library that runs the engine. Greice's own description of her voice ("compliance-first, comfortable naming the gray area") is the most defensible asset in stem cell marketing today, given FTC enforcement on hype-prone competitors.

Active campaigns L30D H

cat. benchmark: 15-30/mo

CTR (link clicks) H

2.83%

healthy for medical

CPM H

$40.86

~2x category benchmark

Patient testimonials collected

0 H

despite "patients in office every other day"

Right-to-Try mentions in creative

0 L

moat not in market

Creative Distribution — What's Working / Broken / Missing

↑ Working

Virtual Consult — Florida State drives ~74% of FB spend with 2.83% CTR H. The offer (free virtual consultation) lowers commitment friction. The geo-targeting (FL state) is correct given SB 1768's jurisdictional limits.

⚠ Broken

Hair Loss campaign ($1,008 spend) sits outside FL SB 1768's authorized scope (orthopedic, pain, wound care) H. Regulatory review required immediately. Plus: 3 campaigns in 31d is category-bottom velocity.

+ Missing

Founder voice, patient testimonials, BetterStem campaigns, Right-to-Try framework messaging. The structural moat isn't in market. Zero BetterStem campaigns running on Meta or Google H.

Section 3 · Category Dynamics

How the regenerative medicine market actually behaves

Seasonality, sub-segment growth, structural shifts, demand triggers. The category is undergoing a regulatory + competitive reshuffling — and MSC + BetterStem sit on the right side of every shift.

⊕ Seasonality — Annual Demand Index

Stem cell consultations follow a dual-peak pattern: January ("New Year, new joints") and Q2-Q3 (active/outdoor → injury → consultation). Q4 is dead — patients defer to year-end HSA + post-holiday financial recovery.

11%

10%

11%

10%

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Pattern logic: Joint pain spikes with activity (Q2-Q3) and resolutions (Jan). Surgery scheduling for fall pulls Sep up. December "year-end HSA spend" produces a small bump but is offset by holiday deferrals. Implication: Q1 + Q2 are the prime acquisition windows. L — pattern is industry-typical, not measured directly from MSC traffic; resolution path is to overlay GA4 sessions across 12+ months once UTM hygiene flows.

⊕ Faster-Growth Sub-Segment

Pediatric Autism Stem Cell

~30-40% YoY L · category-level estimate from Beike + Panama public claims L

Driven by: Duke IMPACT trial validation, Right-to-Try Act precedent expansion (Montana 2023, others pending), parent communities compounding on Facebook + Reddit. BetterStem's window: 36 months before larger US competitors enter.

⊕ Steady-Growth Sub-Segment

Regenerative Orthopedic

~12-15% YoY L · industry analyst estimates L

Driven by: aging population, surgery aversion, FL SB 1768 unlocking advertising, FTC enforcement clearing weak competitors. MSC's 16-year head-start + 8,500 procedures + $50M expansion is structural advantage — but Regenexx (100+ locations) + QC Kinetix (100+ franchises) compound geographic reach faster.

⊕ Shift 1

FL SB 1768 (effective July 1, 2025)

State law authorizes physicians to administer stem cell therapy for orthopedic, pain, wound care. FL is now one of the most permissive US jurisdictions for cash-pay regenerative medicine H. MSC's window is open; the moat is a clock — federal preemption is the long-term risk.

⊕ Shift 2

FTC enforcement intensifying

Stem Cell Institute of America settled $5.15M with FTC (Jan 2025) H. US Stem Cell Inc. (Sunrise, FL) shut down by FDA. Enforcement is clearing the unstructured competitive set — MSC's compliance discipline becomes a moat. Caveat: hype-adjacent campaigns (e.g. Hair Loss outside SB 1768) raise the same risk for MSC.

⊕ Shift 3

Right-to-Try gaining domestic legitimacy

Federal Right-to-Try Act + state expansions (Montana 2023 broadened "severely debilitating"). Domestic alternative to medical tourism is emerging as a category M. BetterStem has first-mover position for pediatric autism — Panama, DVCSTEM, Beike all operate offshore.

⊕ Annual Demand-Trigger Timeline (DTC patient lens)

Jan

"New Year, new joints"

Resolution-driven search peaks. Highest organic intent. Acquisition window 1.

Apr–Jun

Activity → Injury → Consult

Outdoor season starts. Knee/hip/back pain becomes acute. Cortisone alternatives sought. Acquisition window 2.

Jul–Aug

Plateau

Travel + summer pulls attention. Lead volume softens 15-20%.

Sep

Surgery alt-search

Patients evaluating fall surgery scheduling search for alternatives. Acquisition window 3.

Oct–Dec

HSA + holiday

Dec HSA-spend uptick offset by holiday financial deferrals. Lowest acquisition efficiency.

Section 4 · Core Problems

5 problems, sorted by impact severity

Each problem is a Cause → Impact statement, anchored in primary data where possible. Severity badges: red = critical, amber = high, sky = medium.

Problem 1 · Critical

Measurement infrastructure is broken end-to-end

⚠ CRITICAL

0 GA4 key_events tracked across 2,134 L90D sessions; 53% of sessions tagged "(direct)" because UTMs aren't deployed; GHL CRM data sync is empty H.

Cause

No GTM/GA4 conversion-event configuration; agency-produced Meta ads don't carry UTMs to landing pages; GHL CRM → analytics pipeline never built.

Impact

Every CAC, ROAS, and channel decision is a proxy. Cost-per-treated-patient unknowable from primary data. Reallocation = guesswork.

Problem 2 · High

Single-channel, single-creative concentration

HIGH

$3,735 of $5,044 (74%) Meta spend in one campaign · 3 active campaigns in 31 days · 0 BetterStem campaigns H. Category benchmark: 15-30 active creatives/mo.

Cause

Agency-led creative production (low velocity, no founder voice, no UGC pipeline); no internal creative ops; no patient-testimonial collection despite "patients in the office every other day" (Greice).

Impact

Creative-fatigue risk + no resilience. If the one campaign fatigues, 74% of paid acquisition vanishes. Category moat (founder, RTT) sits unused.

Problem 3 · High

BetterStem has no acquisition engine

HIGH

Pre-revenue, ~10 patients in pipeline lifetime, $0 spend, zero email/lifecycle, zero parent-community presence, zero testimonials H.

Cause

Greice prioritized BetterStem in the kickoff but the operational lift (Voice AI on RingCentral, GHL funnels by Jana, financing partner) isn't yet built. No content + no community = no demand pipeline.

Impact

Offshore competitors (Panama 20-yr parent community, DVCSTEM, Beike) compound their head-start every month BetterStem is dark. First-mover advantage on US Right-to-Try is a clock.

Problem 4 · High

Regulatory exposure outside SB 1768 scope

HIGH

$1,008 of Meta spend on a Hair Loss campaign in last 31 days H. Hair restoration falls outside FL SB 1768's authorized scope (orthopedic, pain, wound care). stemcellmia.com also lists autoimmune + neurological conditions on the website that exceed SB 1768.

Cause

Agency-managed paid + WordPress agency-managed site without cross-functional regulatory review. Greice's compliance discipline is high; the supply chain of vendors isn't aligned.

Impact

FTC + FDA enforcement risk. US Stem Cell Inc. (same federal district) was shut down for less. Compliance is the moat — sloppiness erodes it.

Problem 5 · Medium

3,000-4,000 GHL contacts dormant

MEDIUM

3,000-4,000 contacts in GHL that already passed qualification H — zero reactivation campaigns, zero segmentation, zero email infrastructure built on top.

Cause

No internal lifecycle ops. Jana built funnels for BetterStem (per kickoff) but not reactivation flows for MSC's contact base. Marketing has been entirely top-of-funnel.

Impact

Highest-intent pool in the stack is idle. ~$0 CAC reactivation foregone. Category-leading clinics see 20-30% revenue from past-patient lifecycle.

Section 5 · Competitive Landscape

Where MSC + BetterStem sit in the cash-pay regenerative market

Two competitive sets, one positioning system. The combined client sits at a structural advantage on regulatory + founder credibility — and behind on geographic reach + parent-community penetration.

Positioning Map — Regulatory Risk × Patient Accessibility

X-axis: regulatory framework (US-compliant ↔ offshore/unregulated). Y-axis: patient accessibility (mass-market ↔ premium-niche). The combined client sits in the upper-middle: compliant + accessible. Offshore competitors and US enforcement targets cluster opposite corners.

Mass-Market

Premium-Niche

Offshore / Unregulated

US-Compliant Framework

Panama SCI

Mexico clinics

DVCSTEM (Cayman)

Beike Biotech

QC Kinetix

Traditional ortho

Regenexx

Duke (trial)

US Stem Cell Inc. (shut down)

MSC + BetterStem

Strategic position: The combined client occupies the uncontested middle — compliant US framework with accessible-but-not-discount pricing. Offshore competitors (Panama, DVCSTEM, Beike) cannot match domestic legal recourse. Franchise discounters (QC Kinetix) cannot match founder-credibility + 16-yr operational depth. The structural advantage is real; the execution gap is geographic reach + content density.

Creative & Messaging Patterns

How each competitor positions and what hooks land. Client row highlighted.

Brand	Positioning	Messaging Style	Channel Strength	Where they win	Where we win
Regenexx Orthopedic · 100+ MD network	"Surgery alternative for serious athletes." Premium-clinical.	Peer-reviewed evidence-led; physician-credentialed. Outcome registries cited.	Physician licensing + national geo coverage	Published clinical research; geographic reach (100+ vs 2)	Cell quality (allogeneic UC-MSC vs. patient-derived BMC); upsell mastery
QC Kinetix Orthopedic · 100+ franchises	"46,000+ lives transformed." Mass-market accessibility.	Volume social proof; direct-response.	Franchise + call-center + local TV	Price ($5K-$8K entry); national scale	Cell quality; physician-led care vs. NPs; FTC-compliance discipline
Panama Stem Cell Institute Pediatric autism + adult · Panama	"20 years, 80,000+ procedures, Golden Cells." Offshore authority.	Parent-FB-community storytelling; founder Riordan publishes.	Organic + 20yr parent word-of-mouth	Volume (80,000+ procedures) + parent community + Riordan publications	Domestic (no passport, 1-day treatment); Right-to-Try US legal recourse; FTC-compliant copy
DVCSTEM Cayman Islands	"300M culture-expanded UC-MSCs, IRB-approved, Cayman regulation."	Higher-cell-count claim; international medical tourism positioning.	Medical tourism aggregators	Higher cell count (regulatory advantage of culture expansion)	Domestic + cheaper all-in (~$10K-$16K vs. $22K-$30K total); IV-only less invasive
Duke University (IMPACT) Academic clinical trial	"FDA-authorized Phase II, NIH/Marcus Foundation-backed."	Academic gravitas; evidence-led.	Institutional + research community	Free + Duke credibility	Guaranteed treatment (no placebo arm); domestic backup when Duke says no
Miami Stem Cell + BetterStem Orthopedic + autism · FL/HI	16-year practice + Right-to-Try. Compliance-first founder.	Greice's voice is the moat — but absent from current creative.	Meta Ads (3 campaigns) · GHL CRM · WP SEO (8 posts/wk)	—	Right-to-Try moat; EY-recognized founder; only US clinic with full 3-pillar legal framework for autism

Acquisition Strategy — How Each Brand Generates Demand

Brand	Primary Lever	Creative Velocity	Geo Coverage	Lifecycle Leverage	SEO Authority
Regenexx	Physician licensing	Medium	100+ US locations	Patient-registry-driven	High (peer-review citations)
QC Kinetix	Franchise + call center	High (TV + paid social)	100+ franchises	Standardized	Medium
Panama SCI	Parent community + organic	Low (slow + steady)	1 (Panama City)	Word-of-mouth	Medium-High (20yr)
DVCSTEM	Medical tourism aggregators	Medium	1 (Cayman)	Limited	Medium
Duke (IMPACT)	Academic + clinical trial registry	N/A	1 (Durham, NC)	N/A	Very High (academic)
MSC + BetterStem	Meta Ads + Google Ads + WP SEO	Low (3 campaigns / 31d)	2 (Miami + Honolulu)	None active	Low (no topical authority)

Where MSC + BetterStem Sits Today

⊕ Strategic Position

Structural advantage on regulatory + founder + cell-quality. Execution gap on geographic reach, creative velocity, and lifecycle/community.

The combined moat — Greice's EY-recognized operational track record + 16 years + 8,500 procedures + 70-80% upsell discipline + the only US clinic running the full 3-pillar Right-to-Try framework for pediatric autism — is genuinely defensible. It is also genuinely absent from the current creative library. Regenexx out-publishes on clinical evidence; QC Kinetix out-scales on geo; Panama out-communities on parent referrals. MSC + BetterStem's job over 90 days is not to replicate any of those — it's to put the actual moat into market.

The execution gap is closeable in 90 days. Founder-direct creative + patient testimonial collection + Right-to-Try framework messaging + parent-community pilot are all 30-60 day plays. Geographic franchise replication is the 36-month play (BetterStem's stated 5-10 location target).

White Space Opportunities — Uncontested Lanes

Four lanes where no competitor has presence and the combined client has structural fit.

⊕ White Space 1

Right-to-Try Parent Cohort + Outcome Tracking

Structured BetterStem family community with monthly virtual support + standardized 6/12/24-mo autism progression assessments. Generates first-party outcome data + testimonials simultaneously. Panama has informal FB groups; Duke prohibits inter-family contact (blinding); BetterStem can own this lane outright.

Defensibility: First 20-30 founding families = institutional asset. Outcomes data can become BetterStem's first peer-reviewable evidence base.

⊕ White Space 2

Telemedicine Pre-Enrollment via Regional Pediatricians

Partner with 10+ developmental pediatricians (Seattle, Dallas, Chicago, Boston, Denver) for virtual Right-to-Try eligibility screening. Decouples BetterStem from Miami-only friction. Panama can't replicate (no US pediatrician network); Duke is enrollment-bottlenecked.

Defensibility: Network effect. Each regional partnership compounds — first 5 are hard, next 5 are easier.

⊕ White Space 3

Compliant US Autism Playbook (Content Moat)

Founder-authored long-form content explaining Right-to-Try + IRB + FDA-regulated framework. Built once, ranks for years on the exact ICP search terms. Offshore competitors can't write this (would expose their non-compliance); Duke has academic content but not parent-language explainers.

Defensibility: Topical SEO authority on the most defensible terms. Compounding asset, zero CAC at maturity.

⊕ White Space 4

Employer / Self-Insured Bundle Pilots (3-5yr)

Pilot contracts with 1-2 self-insured employer plans (500-2,000 employees) covering MSC orthopedic + BetterStem autism as covered benefits. Generates de-identified outcome data + creates "covered benefit" precedent. No competitor in either category has attempted this.

Defensibility: 3-5 year play. Establishes "autism stem cell as covered benefit" category-first.

Section 6 · Growth Opportunities

5 strategic directions, sized against measurable lift

Each opportunity carries a numeric expected-impact range. Sequencing logic: Foundation (measurement) → Quick wins (CRM) → Mid-term (Google Ads, show rate) → Long-term (BetterStem launch).

Opportunity 1 · Quick (Foundation)

Stitch the measurement layer

QUICK · 14 DAYS

UTMs across all paid placements + GA4 key_events configuration + GHL CRM data sync. Foundation move that unblocks every other lever.

What we'd do

UTM template for Meta + Google + email + landing pages · GA4 events: form_submit, call_click, schedule_consult · GHL CRM daily metrics + leads → analytics layer · attribution dashboard

Expected impact

~80% of KPIs upgrade L→M or M→H confidence · channel reallocation decisions become defensible

Timing

Days 1-14 · first attribution dashboard by Day 21

Opportunity 2 · Quick (Highest ROI)

CRM Reactivation — 3,500 GHL contacts

QUICK · $0 CAC

Segment by last-treatment-date + procedure type + upsell eligibility. 3-email + 2-SMS reactivation flow. Near-zero CAC because every contact already qualified once.

What we'd do

3,000-4,000 contacts segmented (active / lapsed 12mo / lapsed 24mo / dormant) · "It's been a while" series · joint-specific upsell triggers · $10K blended ticket assumption

Expected impact

+$10-30K / mo within 30 days M · 1-3 reactivated patients/mo · ~$0 CAC

Timing

Days 7-21 · first revenue Day 14-30

Opportunity 3 · Mid-term

Google Ads launch + Meta optimization

MID · 30 DAYS

No active Google Ads campaigns running H. Search intent for "stem cell knee Miami" + "Right-to-Try autism US" is the highest-quality acquisition channel — currently uncontested by MSC. Plus pause Hair Loss campaign + diversify Meta beyond single Virtual Consult campaign.

What we'd do

Geo-targeted search + Performance Max for orthopedic; pre-emptive pause + compliance audit on Hair Loss; 5+ Meta variants with founder voice + RTT framework + patient testimonial

Expected impact

+$30-50K / mo M · stated CPL $40-70 target · Meta CPM $40 → $25-30

Timing

Days 14-45 · requires Opp 1 (measurement) to land first

Opportunity 4 · Mid-term

Show rate + close rate optimization

MID · 21 DAYS

Stated MSC funnel: ~60% show, ~60% close. Category benchmark: 65-70% show, 55-65% close. Reminder cadence + pre-consult education + objection-pre-handling can move both rates without new spend.

What we'd do

SMS+email reminder sequence (T-48h, T-24h, T-2h) · pre-consult video from Greice · post-show objection-response sequence · weekly funnel review

Expected impact

+$30K / mo M · show rate 60% → 70%; close rate 60% → 68% · 3-5 incremental patients/mo

Timing

Days 14-35 · revenue impact by Day 30

Opportunity 5 · Long-term

BetterStem launch playbook

LONG · 60 DAYS

Right-to-Try moat + EY-recognized founder = uncontested US position. Path: founder-led content (week 1-3), parent-community pilot (week 3-6), first paid funnel test (week 5-8), telemedicine pre-enrollment partnerships (week 6-12).

What we'd do

Greice founder-direct content series (5 videos × parent objections) · private FB community pilot (50-100 founding members) · first $5K Meta test on autism-parent ICP · regional pediatrician outreach (10 markets)

Expected impact

+$62-125K / mo at maturity L · 5-10 patients/mo × $12.5K · first revenue by Day 60

Timing

Days 30-90 · gated on RingCentral Voice AI + GHL funnel completion

Section 8 · Strategic Arc

Stabilize → Scale → Compound

Sequencing logic — not a tactical to-do list. Stabilize before scale; scale before expand. Each phase compounds the last.

Days 0-30 · Stabilize

Make the engine measurable + capture latent revenue.

The first 30 days fix what's broken under the hood — measurement, attribution, compliance — and unlock the highest-immediate-ROI lever (CRM reactivation). Nothing scales until the data layer is real.

1. Measurement layer (Days 1-14)

UTMs · GA4 events · GHL CRM data sync · attribution dashboard. Pre-condition for all other levers.

2. CRM reactivation pilot (Days 7-21)

Segment 3,500 contacts · 3-email + 2-SMS flow · first reactivated patient by Day 21. $0 CAC, +$10-30K/mo trajectory.

3. Compliance audit (Days 1-14)

Pause Hair Loss campaign · review WP-listed conditions vs. SB 1768 scope · compliance review template per new asset. Moat preservation.

4. Baseline CAC + ROAS (Day 14-30)

First confidence-tagged channel performance review with real data, not stated.

Days 30-60 · Scale

Diversify channels, lift show + close, launch BetterStem.

Days 30-60 use the now-operational measurement layer to make confident reallocation decisions. Google Ads launches, Meta diversifies past one campaign, and the BetterStem engine begins. This phase is about optionality.

5. Google Ads launch (Days 14-45)

Geo-targeted search + Pmax for orthopedic. +$30-50K/mo target.

6. Meta creative diversification (Days 30-50)

5+ variants with founder voice + RTT framework + patient testimonial. CPM $40 → $25-30 target.

7. Show + close rate playbook (Days 14-35)

SMS reminders · pre-consult video · post-consult objection sequence. +$30K/mo.

8. BetterStem founder content (Days 30-60)

5 founder videos × parent objections · first paid funnel test · GHL funnel completion.

Days 60-90 · Compound

Build durable assets — community, content, lifecycle.

Days 60-90 invest in compounding assets that don't decay with creative fatigue. The goal of this phase is to stand up channels that work without ongoing campaign spend.

9. BetterStem parent community pilot (Days 60-90)

50-100 founding member private community · monthly virtual support · standardized outcome tracking. First testimonials harvested.

10. Email/SMS lifecycle (Days 60-90)

Welcome · pre-consult · post-treatment follow-up · referral request flows. Across both brands.

11. Topical SEO content (Days 45-90)

Founder-authored long-form on Right-to-Try + SB 1768 + objection-response. Compounding asset.

12. Regional pediatrician outreach (Days 60-90)

10 markets · BetterStem pre-enrollment partnership template. Decouples from Miami-only friction.

Metric	Healthy	Trigger	Action	Owner
Meta CPM	<$30	>$45	Refresh creative; rotate hooks	Growth
Stated CPL (Meta)	<$60	>$90	Pause + diagnose; check audience saturation	Growth
Cost / treated patient (derived)	<$200	>$350	Reallocate spend; investigate FB lead quality	Growth
GA4 key events / mo	>50	<20	Audit GTM + GA4 config; check conversion fires	Eng
GHL contacts / mo (lead volume)	>450	<350	Source diagnostic; check landing page CVR	Sales
Consult show rate	>65%	<55%	Reminder sequence audit; pre-consult video	Ops
Close rate (after consult)	>55%	<45%	Sales review; objection-response training	Ops

Miami Stem Cell + BetterStemBusiness Review

Funnel Performance & The Primary Growth Constraint

Channel Mix — Imbalance & Dependency Risk

Creative Patterns — What's Winning vs. What's Running

Positioning Map — Regulatory Risk × Patient Accessibility

Creative & Messaging Patterns

Acquisition Strategy — How Each Brand Generates Demand

Where MSC + BetterStem Sits Today

White Space Opportunities — Uncontested Lanes

Miami Stem Cell + BetterStem
Business Review